Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Case-Control Study IDs Several Novel Risk Factors of Post-HCT Melanoma

Key clinical point: Melanoma after HCT has a multifactorial etiology, which underscores the importance of adherence to prevention and screening recommendations

Major finding: Several factors increase post-HCT melanoma risk, including reduced-intensity conditioning with melphalan or fludarabine vs. busulfan (ORs, 2.60, and 2.72, respectively).

Study details: A nested case-control study of 140 patients and 557 matched controls.

Disclosures: This work was supported by the intramural research program of the National Cancer Institute, National Institutes of Health, and the Department of Health & Human Services. The authors reported having no conflicts of interest.


Herr MM et al. J Am Acad Dermatol. 2019 Oct 22. doi: 10.1016/j.jaad.2019.10.034.